Skip to main content

Table 2 Fine-Gray models predicting the incidence of AD, VaD, and death [sHR (95% CI); P value] (n = 1306)

From: Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers

 

Alzheimer’s disease (n = 149)

Vascular dementia (n = 96)

Death (n = 465)

Short rLTL

3.24 (1.404–7.462); P = 0.005

1.09 (0.668–1.780); P = 0.72

1.82 (1.234–2.682); P = 0.002

Long rLTL

1.42 (0.751–2.697); P = 0.28

1.27 (0.758–2.120); P = 0.37

0.82 (0.637–1.056); P = 0.12

APOE ε4-carriers

6.61 (3.592–12.168); P < 0.0001

1.28 (0.841–1.960); P = 0.26

0.70 (0.556–0.882); P = 0.002

Short rLTL/APOE ε4 interaction

0.41 (0.181–0.920); P = 0.03

Long rLTL/APOE ε4 interaction

0.40 (0.169–0.948); P = 0.03

High cholesterol (≥ 240 mg/dL)

1.62 (1.061–2.463); P = 0.02

1.15 (0.736–1.830); P = 0.55

1.82 (1.234–2.682); P = 0.002

Pulse pressure, mmHg

0.99 (0.986–1.006); P = 0.47

1.02 (1.005–1.030); P = 0.005

0.82 (0.637–1.056); P = 0.12

Plasma glucose, mg/dL

0.99 (0.980–1.000); P = 0.04

1.00 (0.994–1.010); P = 0.97

0.70 (0.556–0.882); P = 0.002

Sedimentation rate, mm/h

0.99 (0.984–1.014); P = 0.89

1.03 (0.977–1.040); P = 0.03

1.03 (1.017–1.042); P < 0.0001

Lymphocyte proportion

0.002 (0.00004–0.156); P = 0.004

0.19 (0.012–2.870); P = 0.25

0.58 (0.166–2.057); P = 0.40

Gender, male

0.37 (0.249–0.552); P < 0.0001

2.35 (0.666–3.600); P = 0.03

1.87 (1.531–2.274); P < 0.0001

Age at baseline, years

2.29 (1.719–3.051); P < 0.0001

3.64 (2.571–23.640); P < 0.0001

1.21 (1.087–1.345); P = 0.0004

Age squared

0.995 (0.992–0.997); P < 0.0001

0.991 (0.981–0.990); P < 0.0001

0.999 (0.998–1.000); P = 0.04

Short rLTL time interaction

0.92 (0.869–0.972); P = 0.003

0.95 (0.922–0.983); P = 0.002

Sedimentation rate time interaction

0.996 (0.995–1.000); P = 0.006

0.998 (0.997–0.999); P = 0.005

Lymphocyte proportion time interaction

1.76 (1.266–2.447); P = 0.0007

Gender time interaction

0.92 (0.850–0.986); P = 0.02

 

Pseudo likelihood ratio = 241

Pseudo likelihood ratio = 123

Pseudo likelihood ratio = 480

  1. APOE ε4 apolipoprotein E ε4, CI confidence interval, rLTL residualized leukocyte telomere length, sHR ratio of the subdistribution hazards of Fine-Gray model, accounting for competing risks. Time from baseline, in years, was used as the time scale